innoscripta SE (ISIN: DE000A40QVM8) has reported a strong first half of 2026, with revenue increasing by 43% year-on-year to EUR 63.1 million. Adjusted EBIT rose by 49% to EUR 36.4 million, reflecting the company's operational efficiency and the scalability of its Clusterix platform. The adjusted EBIT margin reached 57.7%, up from 56.9% in the prior-year period. These figures exclude EUR 535 thousand in non-recurring expenses related to corporate restructuring and Group structure establishment.
The German R&D tax allowance (Forschungszulage) continues to be a key growth driver, contributing to the expansion of innoscripta's customer base to over 2,900 clients. The company has further strengthened Clusterix as its central infrastructure for project structuring, data management, and application submissions. This enhancement enables automated data validation, higher data quality, and faster, more standardized processes. It also establishes consistent workflows across different markets, providing a crucial technological foundation for international scaling.
International expansion progressed as planned, with successful market entries into France, the UK, and the US. In France, innoscripta opened its first location near Toulouse and has already secured customers. The UK market entry was marked by a new office in Manchester, operational as of July 1, 2026. In the US, the company has begun serving its first companies in this high-growth market. Clusterix's flexibility in adapting to different regulatory requirements has enabled efficient entry into new markets.
The Management Board confirms its guidance for the full year 2026, expecting Group revenue of at least EUR 140 million and EBIT of at least EUR 80 million, assuming consistent timing of customer application submissions and approvals. Detailed financial figures are available in the Half-Year Report on the company's website in the Investors section.
innoscripta will host a virtual earnings call on H1 2026 results today at 3:00 p.m. CEST. The invitation and dial-in link are available under Investor Events on the company's website.
About innoscripta: innoscripta SE offers Clusterix, a scalable software platform for structured organization and management of research and development activities. Companies use Clusterix to efficiently manage innovation projects, digitize internal processes, and make their R&D activities transparent and scalable.
